Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 18 studies. P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed 1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1068S: Parasitemia And Clinical Malaria In Children On Protease-Inhibitor-Based Therapy DAIDS Number 10661 Research Area Other Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded Pagination Previous page Prev Page 1 Current page 2
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1068S: Parasitemia And Clinical Malaria In Children On Protease-Inhibitor-Based Therapy DAIDS Number 10661 Research Area Other Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
